Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

mplied discussions regarding the potential development and marketing of potential future respiratory products, regarding potential future launches of indacaterol, or regarding potential future revenues from indacaterol. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Novartis will successfully develop or bring to market any additional respiratory products.  Nor can there be any guarantee that indacaterol will be launched in any particular countries, or at any particular time.  Neither can there be any guarantee that indacaterol will achieve any particular levels of revenue in the future. In particular, management's expectations regarding indacaterol could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including unexpected reimbursement difficulties or delays; competition in general; government, industry and general public pricing pressures; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... Dec. 18, 2014 Baptist Health Lexington is the ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation ... Atrial fibrillation is the most common cardiac arrhythmia and ... cases can lead to stroke and possible death. More than ... have atrial fibrillation and the numbers are rapidly increasing ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... SEATTLE, May 30, 2012  Aequus BioPharma, Inc. ("Aequus"), a ... and MTA: CTIC), announced today that its GlycoPolymer technology ... AQB-101 drug candidate, was selected for an oral presentation ... The meeting will be held on May 28-30, 2012, ...
... Medical Center (DMC) and Henry Ford Health System (HFHS) ... renewal and bring jobs to the city of Detroit. ... As part of the economic recovery effort, DMC and ... Health, enabling the company to relocate a medical products ...
Cached Medicine Technology:Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs 2Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs 3Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs 4Cardinal Health, Detroit Medical Center, Henry Ford Health System Announce Unique Collaboration To Promote Urban Renewal 2Cardinal Health, Detroit Medical Center, Henry Ford Health System Announce Unique Collaboration To Promote Urban Renewal 3Cardinal Health, Detroit Medical Center, Henry Ford Health System Announce Unique Collaboration To Promote Urban Renewal 4
(Date:12/21/2014)... Weddingshe.com, an outstanding online supplier of ... released its new selection of Cocktail Dresses for the ... to the newest fashion trends. , “We ... cocktail parties . All of them are offered at ... are making every effort to offer a nice shopping ...
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring wedding dresses was ... designs in this collection, and all of them are ... promises to provide the most fashionable designs to ... fashion trends come and go. If ladies have any ... is ready to assist. , “These new models ...
(Date:12/21/2014)... The number of Mirena lawsuits ( http://www.mirenalawsuit2014.com/ ... in New Jersey, Bernstein Liebhard LLP reports. , According ... the birth control IUD have now been filed in ... women who allege spontaneous migration of the device, which ... other complications they were inadequately warned about by its ...
(Date:12/21/2014)... Over the past 39 years, NES ... of emergency departments across the nation, from quality of ... translated into an innovative suite of tools, systems, and ... enhance the patient experience. , NES Health, a ... management services for hospitals, announced the development and launch ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the table with ... the site has provided its faithful users with everything it ... It uniquely combines the benefits of platforms like Craigslist, Ebay ... masses. Assuring the potent herb’s followers it’s well on ... , Shane Chattin, Owner of Cannabis Classifieds said ...
Breaking Medicine News(10 mins):Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2
... is being issued by the National Press Club:(Logo: ... Club "AFTERNOON NEWSMAKER", Wednesday, April 15, 2009 - ... The Vice President of the Bureau of National ... DR. MICHAEL CHEN, will discuss, ...
... Community SafetyJEFFERSON CITY, Mo. , April 7 ... Parole has launched a new alcohol monitoring Pilot Program ... monitoring on the management of the state,s alcohol-fueled offenders. ... with a documented history of alcohol abuse and with ...
... and Head of Neurochemical Imaging in the Mood Disorders ... the first psychiatrist to be honoured with the Royal College ... , For over 30 years, scientists believed that monoamines ... are low in the brain during episodes of major depression. ...
... Technology Slashes Data Backup Size from 3.2 Terabytes to ... HoursHOPKINTON, Mass., April 7 EMC Corporation (NYSE: ... solutions, today announced that Harvard Vanguard Medical Associates, a ... more than 20 offices across eastern Massachusetts, has deployed ...
... April 7 HIMSS -- Infotech Global, Inc. (IGI) ... Meridian Health, a not-for-profit health system in Central New ... Universal Transfer Form (UTF). The draft UTF was tested ... version in 2008. This work was made possible through ...
... first sensor capable of measuring localized ultrasonic cavitation ... high frequency sound wave is applied. The sensor will ... before they are used on patients. The device recently ... Ultrasonic Industry Association. , Cavitation is used throughout ...
Cached Medicine News:Health News:Missouri DOC Conducting Pilot of 24/7 Alcohol Anklets 2Health News:Missouri DOC Conducting Pilot of 24/7 Alcohol Anklets 3Health News:Harvard Vanguard Cures Data Backup Ills With EMC Avamar 2Health News:Harvard Vanguard Cures Data Backup Ills With EMC Avamar 3Health News:Meridian Health Pilots Electronic Transfer Form 2Health News:Meridian Health Pilots Electronic Transfer Form 3Health News:I'm forever imploding bubbles 2
... CardioSEAL is a second generation device, ... was tested in over 700 patients beginning ... of leading pediatric cardiologists who perform these ... computer simulations, on the engineering bench, and ...
... YAG laser YC-1600 is a lightweight, compact, ... and clinical performance., ,Key Features, , ... Model ,Further weight reduction has been made ... office.,, Aiming Beam Rotation ,(360 degrees ...
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Medicine Products: